Skip to content

Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome

Sequential E2 Levels Not Ovarian Maximal Diameter Estimates Were Correlated With Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02823080
Enrollment
48
Registered
2016-07-06
Start date
2014-10-31
Completion date
2017-05-31
Last updated
2017-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

To evaluate safety and efficacy of 3-day cetrotide therapy started on day of oocyte retrieval (Day-0) in women at high-risk for development of ovarian hyperstimulation syndrome (OHSS) after gonadotropin- releasing hormon agonist induction protocol. Patients & Methods: Forty-eight women fulfilling inclusion criteria underwent ultrasound scanning for maximal ovarian diameter (MOD) estimation and ascites grading. Patients underwent embryo freezing, but study group received 3-day Cetrotide sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8

Detailed description

The current study is conducted at Assisted Reproduction Unit at Almana general Hospital, kingdom of saudi arabia.and other private centers in Egypt. The study protocol was approved by the Local Ethical Committee. The study aimed to include women suspected to be at high risk for development of OHSS during agonist ovarian stimulation protocol.The study includes only women of couples singed written consent to participate in the study, to undergo embryo freezing and to postpone for transfer of cryopreserved embryo. All patients are clinically evaluated for the presence of abdominal pain and if present will be graduated using a numerical pain visual analogue scale (VAS) with 0 means no pain and 10 means severe intolerable pain. Patients are evaluated for the presence of nausea and/or vomiting and sense of abdominal distension. Symptoms are scored using verbal analogue scale as nil, mild, moderate, and severe symptom. Blood samples are obtained under complete aseptic condition for estimation of serum E2 level and determination of hematocrit value (Ht%) and total leucocytic count (TLC). Then, all patients underwent ultrasound scanning for estimation of ovarian measurements that were represented as the maximal ovarian diameter (MOD) and for ascites grading if present. Ultrasound scanning is performed using a 5 megahertz vaginal probe , otherwise a 3.5 megahertz, 2.6 megahertz or 5megahertz abdominal probe is used if visualization using a vaginal probe is compromised. Ascites is graded according to the quantity of fluid accumulation in the peritoneal cavity with the patient in the anti-Trendelenburg position. Women fulfilling inclusion criteria were randomely allocated,using sealed envelops, into two equal groups. Group with embryo freezing alone (Control group) or while the other group additionally receives cetrotide subcutaneous injection in a daily dose of 0.25 mg started on day of oocyte retrieval for 3 days (Study group). Symptomatic treatment for associated symptoms as analgesics, antiemetics and antispasmodics are also prescribed. Patients are categorized according to classification grading of OHSS. Class Clinical features Biochemical features Mild - Abdominal distension/ discomfort * Mild nausea/vomiting * Diarrhea * Ovarian size usually \< 8 cm No clinically important laboratory findings Moderate - Mild features plus * US evidence of ascites - Elevated Ht (\>41%) * Elevated TLC \>15,000/ ml * Hypoproteinemia Severe - Mild & Moderate features plus * Clinically detected ascites * Severe abdominal pain * Intractable nausea * Rapid weight gain (\>1 kg/24 hr) * Pleural effusion * Severe dyspnea * Oliguria/anuria * Low blood/central venous pressures * Syncope * Venous thrombosis * Hemoconcentration (Ht \>55%) * TLC \>25,000/ ml * Serum creatinine \>1.6 mg/dl * creatinine clearance \<50 ml/min * Hyponatremia (Na+\<135milliequivalent per litre) * Hypokalemia (K+ \< 5 milliequivalent per litre) * Elevated liver enzymes Critical - Severe features plus * Anuria/ Acute renal failure * Arrhythmia * Pericardial effusion * Massive hydrothorax * Thrombo-embolism * Arterial thrombosis * (ARDS)Adult respiratory distress syndrome * Sepsis - Worsening of biochemical findings seen with severe OHSS US: Ultrasound; Ht%:Ht; Hematocrit value; TLC: Total leucocytic count: ARDS; adult respiratory distress syndrome. All patients are managed as outpatients unless management of severe symptoms necessitated hospital admission. Pain scores, serum E2 levels and MOD are evaluated daily. Patients are evaluated for associated symptoms previously determined during clinical evaluation, ascites grading and TLC and Ht value were evaluated at 3 and 6 days and on end of the trial on the 8th day after oocyte retrieval.

Interventions

study group received 3-day Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites control (24 patients) did not receive Cetrorelix Acetate. Grading were re-evaluated on Day-3, 6 and 8.

Sponsors

Benha University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

1. number of retrieved oocytes was ≥20 2. mean number of follicles with a diameter of \>16 mm was ≥18 3. serum E2 concentrations of ≥3500 pg/ml 4. ovarian diameter on the day of ovum retrieval of \>10 cm 5. presentation of evident symptoms of OHSS on the day of aspiration .

Exclusion criteria

1- Absence of one or more of the items of the inclusion criteria.

Design outcomes

Primary

MeasureTime frameDescription
Daily Maximal Ovarian Diameter8 daysMOD (maximal ovarian diameter in mm) were evaluated daily.
Daily Serum E2 Levels8 daysSerum E2 levels (Serum E2 level in picograms/ml) were evaluated daily.

Secondary

MeasureTime frameDescription
Daily Hematocrits Value0-8 days.Blood samples were obtained under complete aseptic condition for determination of hematocrits value (Ht%)
Daily Total Leucocytic Count0 -8days.TLC(x 1ooo cells/ml)
Ultrasound Detected Severity Grades of Ascites From Days 0-80-8 days-US detected severity grades of ascites determined at Day -0, Day -3 and Day -8.
Daily Numerical Pain Visual Analogue Scale Score8 days.-All patients were clinically evaluated for the presence of abdominal pain and if present was graduated using a numerical pain visual analogue scale (VAS) with 0 means no pain and 10 means severe intolerable pain .

Other

MeasureTime frameDescription
Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy0-6 days-severity grades of gastrointestinal manifestations determined at Day -0,Day -3 and Day -6.

Countries

Egypt

Participant flow

Participants by arm

ArmCount
Cetrotide
study group (24 patients = intervention) received intervention for 3-daysCetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.
24
no Cetrotide
control group (24 patients) did not receive 3-daysCetrorelix Acetate (no intervention). Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.
24
Total48

Baseline characteristics

CharacteristicCetrotideno CetrotideTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
24 Participants24 Participants48 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
24 Participants24 Participants48 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
0 Participants0 Participants0 Participants
Region of Enrollment
Egypt
12 participants12 participants24 participants
Region of Enrollment
Saudi Arabia
12 participants12 participants24 participants
Sex: Female, Male
Female
24 Participants24 Participants48 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 240 / 24
other
Total, other adverse events
0 / 240 / 24
serious
Total, serious adverse events
0 / 240 / 24

Outcome results

Primary

Daily Maximal Ovarian Diameter

MOD (maximal ovarian diameter in mm) were evaluated daily.

Time frame: 8 days

ArmMeasureGroupValue (MEAN)Dispersion
CetrotideDaily Maximal Ovarian DiameterDay-19.3 mmStandard Deviation 4.6
CetrotideDaily Maximal Ovarian DiameterDay-57.8 mmStandard Deviation 4
CetrotideDaily Maximal Ovarian DiameterDay-38.7 mmStandard Deviation 4.3
CetrotideDaily Maximal Ovarian DiameterDay-67.5 mmStandard Deviation 4.2
CetrotideDaily Maximal Ovarian DiameterDay-29.1 mmStandard Deviation 4.2
CetrotideDaily Maximal Ovarian DiameterDay-77.3 mmStandard Deviation 4
CetrotideDaily Maximal Ovarian DiameterDay-48.5 mmStandard Deviation 4.3
CetrotideDaily Maximal Ovarian DiameterDay-87.1 mmStandard Deviation 3.7
CetrotideDaily Maximal Ovarian DiameterDay-09.4 mmStandard Deviation 4.5
no CetrotideDaily Maximal Ovarian DiameterDay-87.9 mmStandard Deviation 4.2
no CetrotideDaily Maximal Ovarian DiameterDay-010.4 mmStandard Deviation 5.8
no CetrotideDaily Maximal Ovarian DiameterDay-110.2 mmStandard Deviation 5.6
no CetrotideDaily Maximal Ovarian DiameterDay-29.6 mmStandard Deviation 4.6
no CetrotideDaily Maximal Ovarian DiameterDay-39.4 mmStandard Deviation 4.9
no CetrotideDaily Maximal Ovarian DiameterDay-49.2 mmStandard Deviation 4.7
no CetrotideDaily Maximal Ovarian DiameterDay-59 mmStandard Deviation 4.6
no CetrotideDaily Maximal Ovarian DiameterDay-68.5 mmStandard Deviation 4.6
no CetrotideDaily Maximal Ovarian DiameterDay-78.2 mmStandard Deviation 4.5
p-value: <0.05ANOVA
Primary

Daily Serum E2 Levels

Serum E2 levels (Serum E2 level in picograms/ml) were evaluated daily.

Time frame: 8 days

ArmMeasureGroupValue (MEAN)Dispersion
CetrotideDaily Serum E2 LevelsDay-61173 picograms/mlStandard Deviation 180
CetrotideDaily Serum E2 LevelsDay-22772 picograms/mlStandard Deviation 1456
CetrotideDaily Serum E2 LevelsDay-8902 picograms/mlStandard Deviation 66
CetrotideDaily Serum E2 LevelsDay-32067 picograms/mlStandard Deviation 900
CetrotideDaily Serum E2 LevelsDay-04761 picograms/mlStandard Deviation 940
CetrotideDaily Serum E2 LevelsDay-41452 picograms/mlStandard Deviation 617
CetrotideDaily Serum E2 LevelsDay-7969 picograms/mlStandard Deviation 118
CetrotideDaily Serum E2 LevelsDay-51173 picograms/mlStandard Deviation 180
CetrotideDaily Serum E2 LevelsDay-13397 picograms/mlStandard Deviation 1361
no CetrotideDaily Serum E2 LevelsDay-51914 picograms/mlStandard Deviation 965
no CetrotideDaily Serum E2 LevelsDay-61544 picograms/mlStandard Deviation 812
no CetrotideDaily Serum E2 LevelsDay-71275 picograms/mlStandard Deviation 588
no CetrotideDaily Serum E2 LevelsDay-05004 picograms/mlStandard Deviation 792
no CetrotideDaily Serum E2 LevelsDay-14212 picograms/mlStandard Deviation 950
no CetrotideDaily Serum E2 LevelsDay-23620 picograms/mlStandard Deviation 1037
no CetrotideDaily Serum E2 LevelsDay-33592 picograms/mlStandard Deviation 862
no CetrotideDaily Serum E2 LevelsDay-42570 picograms/mlStandard Deviation 914
no CetrotideDaily Serum E2 LevelsDay-81044 picograms/mlStandard Deviation 200
p-value: <0.05ANOVA
Secondary

Daily Hematocrits Value

Blood samples were obtained under complete aseptic condition for determination of hematocrits value (Ht%)

Time frame: 0-8 days.

ArmMeasureGroupValue (MEAN)Dispersion
CetrotideDaily Hematocrits ValueDay-042.2 percentgeStandard Deviation 5.2
CetrotideDaily Hematocrits ValueDay-338.7 percentgeStandard Deviation 3.3
CetrotideDaily Hematocrits ValueDay-637.3 percentgeStandard Deviation 2.5
CetrotideDaily Hematocrits ValueDay-836.8 percentgeStandard Deviation 2.6
no CetrotideDaily Hematocrits ValueDay-837.5 percentgeStandard Deviation 1.5
no CetrotideDaily Hematocrits ValueDay-039.8 percentgeStandard Deviation 4.2
no CetrotideDaily Hematocrits ValueDay-638 percentgeStandard Deviation 3.1
no CetrotideDaily Hematocrits ValueDay-338.8 percentgeStandard Deviation 3.3
Secondary

Daily Numerical Pain Visual Analogue Scale Score

-All patients were clinically evaluated for the presence of abdominal pain and if present was graduated using a numerical pain visual analogue scale (VAS) with 0 means no pain and 10 means severe intolerable pain .

Time frame: 8 days.

ArmMeasureGroupValue (MEAN)Dispersion
CetrotideDaily Numerical Pain Visual Analogue Scale ScoreDay-50.92 units on a scaleStandard Deviation 1.1
CetrotideDaily Numerical Pain Visual Analogue Scale ScoreDay-60.33 units on a scaleStandard Deviation 0.6
CetrotideDaily Numerical Pain Visual Analogue Scale ScoreDay-05.3 units on a scaleStandard Deviation 1.6
CetrotideDaily Numerical Pain Visual Analogue Scale ScoreDay-14.3 units on a scaleStandard Deviation 1.3
CetrotideDaily Numerical Pain Visual Analogue Scale ScoreDay-23.6 units on a scaleStandard Deviation 1
CetrotideDaily Numerical Pain Visual Analogue Scale ScoreDay-32.3 units on a scaleStandard Deviation 1.8
CetrotideDaily Numerical Pain Visual Analogue Scale ScoreDay-41.6 units on a scaleStandard Deviation 1.2
CetrotideDaily Numerical Pain Visual Analogue Scale ScoreDay-70.17 units on a scaleStandard Deviation 0.38
CetrotideDaily Numerical Pain Visual Analogue Scale ScoreDay-80.13 units on a scaleStandard Deviation 0.34
no CetrotideDaily Numerical Pain Visual Analogue Scale ScoreDay-81.1 units on a scaleStandard Deviation 1.7
no CetrotideDaily Numerical Pain Visual Analogue Scale ScoreDay-53.7 units on a scaleStandard Deviation 2
no CetrotideDaily Numerical Pain Visual Analogue Scale ScoreDay-34.6 units on a scaleStandard Deviation 1.8
no CetrotideDaily Numerical Pain Visual Analogue Scale ScoreDay-71.6 units on a scaleStandard Deviation 1.1
no CetrotideDaily Numerical Pain Visual Analogue Scale ScoreDay-05.4 units on a scaleStandard Deviation 1.7
no CetrotideDaily Numerical Pain Visual Analogue Scale ScoreDay-44.5 units on a scaleStandard Deviation 1.4
no CetrotideDaily Numerical Pain Visual Analogue Scale ScoreDay-15 units on a scaleStandard Deviation 1.3
no CetrotideDaily Numerical Pain Visual Analogue Scale ScoreDay-62.4 units on a scaleStandard Deviation 1.1
no CetrotideDaily Numerical Pain Visual Analogue Scale ScoreDay-24.9 units on a scaleStandard Deviation 1.8
p-value: <0.05ANOVA
Secondary

Daily Total Leucocytic Count

TLC(x 1ooo cells/ml)

Time frame: 0 -8days.

ArmMeasureGroupValue (MEAN)Dispersion
CetrotideDaily Total Leucocytic CountDay-012.75 1000 cells/mlStandard Deviation 3.1
CetrotideDaily Total Leucocytic CountDay-311.5 1000 cells/mlStandard Deviation 2.8
CetrotideDaily Total Leucocytic CountDay-611 1000 cells/mlStandard Deviation 1.9
CetrotideDaily Total Leucocytic CountDay-89.75 1000 cells/mlStandard Deviation 3.1
no CetrotideDaily Total Leucocytic CountDay-810.1 1000 cells/mlStandard Deviation 2.2
no CetrotideDaily Total Leucocytic CountDay-011.6 1000 cells/mlStandard Deviation 3.7
no CetrotideDaily Total Leucocytic CountDay-611.2 1000 cells/mlStandard Deviation 3.6
no CetrotideDaily Total Leucocytic CountDay-311.3 1000 cells/mlStandard Deviation 3.6
Secondary

Ultrasound Detected Severity Grades of Ascites From Days 0-8

-US detected severity grades of ascites determined at Day -0, Day -3 and Day -8.

Time frame: 0-8 days

ArmMeasureGroupValue (NUMBER)
CetrotideUltrasound Detected Severity Grades of Ascites From Days 0-8Low grade ascitis at Day-821 US detected ascitis
CetrotideUltrasound Detected Severity Grades of Ascites From Days 0-8Low grade ascitis at Day-08 US detected ascitis
CetrotideUltrasound Detected Severity Grades of Ascites From Days 0-8moderate grade ascitis at Day-016 US detected ascitis
CetrotideUltrasound Detected Severity Grades of Ascites From Days 0-8severe grade ascitis at Day-30 US detected ascitis
CetrotideUltrasound Detected Severity Grades of Ascites From Days 0-8moderate grade ascitis at Day-36 US detected ascitis
CetrotideUltrasound Detected Severity Grades of Ascites From Days 0-8Low grade ascitis at Day-318 US detected ascitis
CetrotideUltrasound Detected Severity Grades of Ascites From Days 0-8moderate grade ascitis at Day-83 US detected ascitis
CetrotideUltrasound Detected Severity Grades of Ascites From Days 0-8severe grade ascitis at Day-80 US detected ascitis
CetrotideUltrasound Detected Severity Grades of Ascites From Days 0-8severe grade ascitis at Day-00 US detected ascitis
no CetrotideUltrasound Detected Severity Grades of Ascites From Days 0-8severe grade ascitis at Day-82 US detected ascitis
no CetrotideUltrasound Detected Severity Grades of Ascites From Days 0-8severe grade ascitis at Day-00 US detected ascitis
no CetrotideUltrasound Detected Severity Grades of Ascites From Days 0-8severe grade ascitis at Day-33 US detected ascitis
no CetrotideUltrasound Detected Severity Grades of Ascites From Days 0-8Low grade ascitis at Day-06 US detected ascitis
no CetrotideUltrasound Detected Severity Grades of Ascites From Days 0-8Low grade ascitis at Day-313 US detected ascitis
no CetrotideUltrasound Detected Severity Grades of Ascites From Days 0-8Low grade ascitis at Day-817 US detected ascitis
no CetrotideUltrasound Detected Severity Grades of Ascites From Days 0-8moderate grade ascitis at Day-018 US detected ascitis
no CetrotideUltrasound Detected Severity Grades of Ascites From Days 0-8moderate grade ascitis at Day-38 US detected ascitis
no CetrotideUltrasound Detected Severity Grades of Ascites From Days 0-8moderate grade ascitis at Day-85 US detected ascitis
Other Pre-specified

Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy

-severity grades of gastrointestinal manifestations determined at Day -0,Day -3 and Day -6.

Time frame: 0-6 days

ArmMeasureGroupValue (NUMBER)
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymoderate Vomiting at Day-30 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymild Nausea at Day-34 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapysevere Vomiting at Day-30 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymoderate Nausea at Day-60 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of TherapyNil Vomiting at Day-624 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymild Nausea at Day-08 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymild Vomiting at Day-60 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapysevere Nausea at Day-60 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymoderat Vomiting at Day-60 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymoderate Nausea at Day-31 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapysevere Vomiting at Day-60 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of TherapyNil Vomiting at Day-014 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of TherapyNil Abdominal distension at Day-05 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of TherapyNil Nausea at Day-05 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymild Abdominal distension at Day-08 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymild Vomiting at Day-07 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymoderate Abdominal distension at Day-09 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapysevere Nausea at Day-30 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapysevere Abdominal distension at Day-02 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymoderatel Vomiting at Day-02 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of TherapyNil Abdominal distension at Day-315 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymoderate Nausea at Day-07 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymild Abdominal distension at Day-38 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapysevere Vomiting at Day-01 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymoderate Abdominal distension at Day-31 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of TherapyNil Nausea at Day-624 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapysevere Abdominal distension at Day-30 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of TherapyNil Vomiting at Day-324 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of TherapyNil Abdominal distension at Day-624 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of TherapyNil Nausea at Day-319 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymild Abdominal distension at Day-60 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymild Vomiting at Day-30 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymoderate Abdominal distension at Day-60 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymild Nausea at Day-60 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapysevere Abdominal distension at Day-60 GI manifestations
CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapysevere Nausea at Day-04 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapysevere Abdominal distension at Day-60 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapysevere Nausea at Day-05 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of TherapyNil Nausea at Day-312 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of TherapyNil Nausea at Day-06 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymild Nausea at Day-07 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymoderate Nausea at Day-06 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymild Nausea at Day-38 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymoderate Nausea at Day-34 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapysevere Nausea at Day-30 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of TherapyNil Nausea at Day-622 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymild Nausea at Day-62 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymoderate Nausea at Day-60 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapysevere Nausea at Day-60 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of TherapyNil Vomiting at Day-012 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymild Vomiting at Day-08 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymoderatel Vomiting at Day-04 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapysevere Vomiting at Day-00 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of TherapyNil Vomiting at Day-320 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymild Vomiting at Day-34 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymoderate Vomiting at Day-30 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapysevere Vomiting at Day-30 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of TherapyNil Vomiting at Day-624 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymild Vomiting at Day-60 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymoderat Vomiting at Day-60 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapysevere Vomiting at Day-60 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of TherapyNil Abdominal distension at Day-04 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymild Abdominal distension at Day-07 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymoderate Abdominal distension at Day-010 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapysevere Abdominal distension at Day-03 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of TherapyNil Abdominal distension at Day-39 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymild Abdominal distension at Day-312 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymoderate Abdominal distension at Day-33 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapysevere Abdominal distension at Day-30 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of TherapyNil Abdominal distension at Day-620 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymild Abdominal distension at Day-64 GI manifestations
no CetrotideResolution of Gastrointestinal Manifestations Determined Prior to Start of Therapymoderate Abdominal distension at Day-60 GI manifestations
p-value: <0.05ANOVA

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026